Our Top Pick for conservative investors for the coming year is a company that went through a management overhaul in 2015, leaving investors uncertain about the company's future, observes Crista Huff, editor of Cabot Undervalued Stocks Advisor.
Mattel (MAT) markets toys globally under the brand names Mattel, Fisher-Price, RoseArt, Barbie, AmericanGirl and many more, including strategic relationships with Disney (DIS), Google (GOOGL) and YouTube.
As a result of its prior overhaul, the stock got left in the dust. Consumer goods stocks were additionally tossed aside during the post-election stock market run-up.
That gives investors a buying opportunity in the sector's undervalued growth stocks, including MAT.
Mattel's earnings per share, which will finish 2016 with weak 1-2% growth (December year-end), are expected to grow 38% in 2017!
This mid-cap stock's 2017 price/earnings ratio is 16, and the dividend yield is a huge 5.4%. Mattel typically increases the dividend about once per year.
Hot Undervalued Stocks To Invest In Right Now: Carlisle Companies Incorporated(CSL)
Advisors' Opinion:- [By Shane Hupp]
Get a free copy of the Zacks research report on Carlisle Companies (CSL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Joseph Griffin]
SG Americas Securities LLC trimmed its position in Carlisle Companies (NYSE:CSL) by 5.9% during the 1st quarter, Holdings Channel reports. The institutional investor owned 11,215 shares of the conglomerate’s stock after selling 706 shares during the quarter. SG Americas Securities LLC’s holdings in Carlisle Companies were worth $1,171,000 at the end of the most recent reporting period.
- [By Ethan Ryder]
West Pharmaceutical Services (NYSE: WST) and Carlisle Companies (NYSE:CSL) are both mid-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.
- [By Lisa Levin] Gainers Daré Bioscience, Inc. (NASDAQ: DARE) shares jumped 56.69 percent to close at $1.27 on Wednesday on news that the company entered into worldwide license agreement for Juniper Pharmaceuticals' intravaginal ring technology platform. Vicor Corporation (NASDAQ: VICR) rose 26.84 percent to close at $37.10. Vicor posted Q1 earnings of $0.10 per share on sales of $65.2 million. AGM Group Holdings Inc. (NASDAQ: AGMH) climbed 25.56 percent to close at $10.61. Travelzoo (NASDAQ: TZOO) gained 24.7 percent to close at $9.75 following strong Q1 results. Intrepid Potash, Inc. (NYSE: IPI) shares climbed 19.24 percent to close at $4.71. China Customer Relations Centers, Inc. (NASDAQ: CCRC) rose 18.73 percent to close at $18.64. Genprex, Inc. (NASDAQ: GNPX) climbed 18.28 percent to close at $5.89. Genprex expanded its operations to Cambridge, Mass. Scorpio Tankers Inc. (NYSE: STNG) rose 13.92 percent to close at $2.70 following Q1 results. Rocky Brands, Inc. (NASDAQ: RCKY) shares surged 13.57 percent to close at $23.85 after reporting Q1 results. Resonant Inc. (NASDAQ: RESN) shares rose 12.5 percent to close at $4.14 on Wednesday. USANA Health Sciences, Inc. (NYSE: USNA) jumped 11.24 percent to close at $106.85 following Q1 results. SUPERVALU Inc. (NYSE: SVU) rose 11.16 percent to close at $16.24 after the company reported Q4 results and agreed to sell and leaseback eight distribution centers for an aggregate purchase price of $483 million. K12 Inc. (NYSE: LRN) shares gained 10.74 percent to close at $15.36 following Q3 results. Tupperware Brands Corporation (NYSE: TUP) rose 9.15 percent to close at $46.28 as the company posted in-line quarterly earnings. Six Flags Entertainment Corporation (NYSE: SIX) shares climbed 8.49 percent to close at $64.18 as the company posted a narrower-than-expected loss for its first quarter. Carlisle Companies Incorporated (NYSE: CSL) gained 8.2 percent to close at $107.94 af
Hot Undervalued Stocks To Invest In Right Now: CHS Inc(CHSCL)
Advisors' Opinion:- [By Joseph Griffin]
CHS (NASDAQ:CHSCL) was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued on Friday.
Hot Undervalued Stocks To Invest In Right Now: Keryx Biopharmaceuticals, Inc.(KERX)
Advisors' Opinion:- [By Ethan Ryder]
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Wednesday, August 8th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). equities research analysts expect that Keryx Biopharmaceuticals will post -0.61 earnings per share for the current fiscal year.
- [By Logan Wallace]
Keryx Biopharmaceuticals (NASDAQ:KERX) has been assigned an average rating of “Hold” from the eight brokerages that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, five have given a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $6.00.
- [By Maxx Chatsko]
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) dropped nearly 20% last month, according to data from S&P Global Market Intelligence. The pharma company announced second-quarter and first-half 2018 results that included disappointing sales revenue for its only drug, Auryxia. As a result, sales lagged behind consensus estimates despite delivering strong year-over-year growth.
- [By Stephan Byrd]
Shares of Keryx Biopharmaceuticals (NASDAQ:KERX) have received a consensus rating of “Hold” from the eight brokerages that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, five have given a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $6.00.
- [By Brian Feroldi]
In response to the companies signing a merger agreement, shares of Akebia Therapeutics (NASDAQ:AKBA) and Keryx Biopharmaceuticals (NASDAQ:KERX) fell 18% and 12%, respectively, as of 10:47 a.m. EDT on Thursday.
- [By Shane Hupp]
Keryx Biopharmaceuticals (NASDAQ:KERX)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a report issued on Thursday. They currently have a $9.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would indicate a potential upside of 174.39% from the stock’s current price.
Hot Undervalued Stocks To Invest In Right Now: VIVUS, Inc.(VVUS)
Advisors' Opinion:- [By Money Morning News Team]
Seadrill's rally demonstrates how profitable penny stocks can be for savvy investors. With Seadrill's gains already on the books, we'll look at a stock that's on track to generate tremendous returns – a small cap that just completed a groundbreaking acquisition with huge profit potential…
Penny Stock Current Share Price Law Week's Gain Seadrill Ltd. (NYSE: SDRL) $0.58 98.74% Vivis Inc. (Nasdaq: VVUS) $0.83 59.97% MEI Pharma Inc. (Nasdaq: MEIP) $3.45 43.40% Transenterix Inc. (NYSE: TRXC) $3.15 35.72% Akers Biosciences Inc. (Nasdaq: AKER) $0.65 34.38% Galectin Therapeutics Inc. (Nasdaq: GALT) $4.54 32.58% Phoenix New Media Ltd. (NYSE ADR: FENG) $5.65 32.22% Heat Biologics Inc. (Nasdaq: HTBX) $1.73 31.37% Bright Scholar Education Ltd. (NYSE ADR: BEDU) $18.51 29.03% 21 Vianet Group Inc. (Nasdaq: VNET) $7.36 28.72%These gains are incredibly exciting. However, not all penny stocks are equally strong investments.
- [By Money Morning Staff Reports]
But Blink and our other penny stocks to watch are unlikely to continue to lock in such spectacular gains in June. After looking at our 10 top penny stocks to watch this month, we'll show you a small-cap stock with great profit potential in its future…
Penny Stock Current Share Price Law Month's Gain Blink Charging Co. (Nasdaq: BLNK) $7.07 439.85% Senes Tech Inc. (Nasdaq: SNES) $1.27 175.40% Vivis Inc. (Nasdaq: VVUS) $0.77 150.41% Adomani Inc. (Nasdaq: ADOM) $1.49 137.68% NF Energy Saving Co. (Nasdaq: NFEC) $2.34 134.88% Vaalco Energy Inc. (NYSE: EGY) $2.15 109.06% Heat Biologics Inc. (Nasdaq: HTBX) $2.35 99.12% ArQule Inc. (Nasdaq: ARQL) $4.88 90.74% LiqTech International Inc. (NYSE: LIQT) $0.66 85.60% Transenterix Inc. (NYSE: TRXC) $3.46 77.84%While last month's gains are tremendous, they also illustrate the inherent dangers that come with investing in penny stocks.
- [By Logan Wallace]
Media stories about VIVUS (NASDAQ:VVUS) have been trending somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. VIVUS earned a news impact score of 0.13 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 47.022479468622 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Hot Undervalued Stocks To Invest In Right Now: Leggett & Platt, Incorporated(LEG)
Advisors' Opinion:- [By Max Byerly]
Cullen Frost Bankers Inc. boosted its stake in shares of Leggett & Platt, Inc. (NYSE:LEG) by 24.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,849 shares of the company’s stock after buying an additional 1,715 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Leggett & Platt were worth $395,000 as of its most recent SEC filing.
- [By ]
Leggett & Platt, Inc. (NYSE: LEG) increased its dividend by almost 6 percent to $0.38 per share from $0.36 per share in May of 2018 at the annual meeting.
- [By Joseph Griffin]
Shares of LEG Immobilien AG (FRA:LEG) have been assigned an average rating of “Buy” from the nineteen research firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating and thirteen have assigned a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is €101.62 ($118.16).
No comments:
Post a Comment